Date: 2016-02-15
Type of information: Collaboration agreement
Compound: armed antibody products
Company: Philogen (Italy) Abbvie (USA - IL)
Therapeutic area:
Type agreement: R&D collaboration
Action mechanism:
Disease:
Details: * On February 15, 2016, Philogen announced that they have entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products. The first agreement between the two companies is focused on osteoarthritis.
Financial terms: No financial details of the agreement were released.
Latest news:
